

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
04 May 2023 (04.05.2023)



(10) International Publication Number
WO 2023/077156 A1

(51) International Patent Classification:

C07K 14/705 (2006.01) A61P 35/00 (2006.01)
A61K 38/17 (2006.01) C12N 15/62 (2006.01)

(21) International Application Number:

PCT/US2022/079052

(22) International Filing Date:

01 November 2022 (01.11.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/274,232	01 November 2021 (01.11.2021)	US
63/320,628	16 March 2022 (16.03.2022)	US
63/325,568	30 March 2022 (30.03.2022)	US
63/369,836	29 July 2022 (29.07.2022)	US

(71) Applicant: **SHATTUCK LABS, INC.** [US/US]; 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US).

(72) Inventors: **SCHREIBER, Taylor**; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US).


FROMM, George; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US). **SHUPTRINE, Casey**; c/o Shattuck Labs, Inc., 500 W. 5th Street, Suite 1200, Austin, TX 78701 (US).

(74) Agent: **ALTIERI, Stephen, L.** et al.; Morgan, Lewis & Bockius LLP, 1701 Market Street, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: MODIFIED MRNA THERAPEUTICS

FIG. 3



(57) Abstract: There is a need to adapt nucleic acid delivery strategies to provide alternative mechanisms for therapeutic proteins to provide more convenient and/or more effective treatment. The present disclosure relates to, inter alia, compositions and methods for nucleic acid-based delivery of chimeric proteins that find use in the treatment of a disease or disorder such as selected from cancer, autoimmunity, fibrotic disease, and other inflammatory disorders.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*